Bank of America
UNCY icon

Bank of America’s Unicycive Therapeutics UNCY Stock Holding History

Bank of America’s Portfolio UNCY Stock Details UNCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$194K Buy
29,530
+29,378
+19,328% +$193K ﹤0.01% 5370
2025
Q4 		$877 Sell
152
-675
-82% -$3.6K ﹤0.01% 6482
2025
Q3 		$3.61K Buy
827
+763
+1,192% +$3.33K ﹤0.01% 7336
2025
Q2 		$305 Buy
64
+21
+49% +$130 ﹤0.01% 7767
2025
Q1 		$246 Buy
43
+2
+5% +$12 ﹤0.01% 7648
2024
Q4 		$322 Buy
41
+8
+24% +$44 ﹤0.01% 7494
2024
Q3 		$135 Buy
33
+11
+50% +$44 ﹤0.01% 7656
2024
Q2 		$112 Buy
+22
New +$216 ﹤0.01% 7677
2023
Q1 		– Sell
-1
Closed -$5 – 8285
2022
Q4 		$5 Buy
+1
New +$7 ﹤0.01% 8135
2022
Q1 		– Sell
-2
Closed – – 8780
2021
Q4 		$0 Buy
+2
New +$50 ﹤0.01% 8653

Other funds holding UNCY

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America's UNCY Position: Q1 2026 in Review

Bank of America increased its Unicycive Therapeutics (UNCY) stake by 19,328% in Q1 2026, buying an estimated $193K and bringing the position to 29,530 shares worth $194K. The position accounts for ﹤0.01% of the portfolio, ranked #5370.

Bank of America first reported a position in UNCY in Q4 2021 and has held it in 10 quarters since. 51 funds tracked by Wall St. Rank hold UNCY as of Q1 2026.

  • Bank of America held 29,530 shares of Unicycive Therapeutics worth $194K as of Q1 2026.
  • Bank of America bought 29,378 Unicycive Therapeutics shares in Q1 2026, an estimated $193K.
  • Unicycive Therapeutics made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #5370 holding.
  • Bank of America first reported a position in Unicycive Therapeutics in Q4 2021 and has held it in 10 quarters since.
  • 51 funds tracked by Wall St. Rank held Unicycive Therapeutics as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.